MEDICALgorithmics S.A. (WSE:MDG) and US subsidiary Medi-Lynx Cardiac Monitoring LLC, today announced that the PocketECG mobile cardiac telemetry system reports will now include enhanced physical activity monitoring data. The addition of a unique accelerometer feature will enable health care professionals to differentiate between heart rate changes triggered by physical activity and those triggered by an arrhythmia. The new feature will also allow them to determine the correlation between patient’s physical activity, patient’s symptoms and various types of arrhythmia. The new feature will be previewed in the exhibition hall at this year’s Heart Rhythm Society’s Scientific Sessions in Chicago, May 10-13, Booth 1317.
“PocketECG is the only FDA approved mobile cardiac telemetry device that records and annotates every QRS complex and recognizes its morphology,” said Marek Dziubinski, PhD, Chief Executive Officer of MEDICALgorithmics S.A. “This, when combined with the physical activity monitoring feature, allows us to provide better correlation data and enable specialists to derive more meaningful HR measurements to better guide treatment decisions.”
Many cardiac conditions cannot be diagnosed with a single ECG test, or by using standard diagnostic methods of arrhythmia detection. PocketECG makes precise diagnosis possible through full disclosure monitoring and transmission of a patient’s ECG for up to 30 days, labeling and morphology-based classification of every heartbeat, as well as true statistical reporting of the detected arrhythmia.
“PocketECG’s reports show a physician everything they need to know to guide treatment decisions,” said Dr. Dziubinski. “The system always detects the onset, offset, and the most extreme part of each arrhythmia episode — not just the “snapshots.” This feature overcomes the limitations of all other mobile cardiac telemetry systems ensuring a more accurate diagnosis.”
PocketECG is the only FDA approved unified arrhythmia diagnostic system. PocketECG was created in consultation with electrophysiologists, cardiologists and nurses to address the gaps and limitations of arrhythmia detection and diagnostics methods. As a result, PocketECG’s online arrhythmia monitoring system offers unique technical capabilities that combine benefits of various methods while eliminating traditional limitations. PocketECG offers full disclosure, morphology-based online monitoring, where all heartbeats are labeled and the arrhythmia detection results are statistically summarized in the reports. The reports present meaningful ECG strips showing extreme cases of detected arrhythmia and include onset and offset, and the extreme part of each arrhythmia episode. The new physical activity analysis section in the report presents the correlation between the patient’s physical activity, the arrhythmia and the symptoms.
About Arrhythmia and Atrial Fibrillation
Arrhythmia refers to any change, or abnormality in the sequence of electrical impulses that influence heart rhythms. Atrial Fibrillation (AF), affecting almost three million Americans, is a form of arrhythmia resulting in a quivering or irregular heartbeat. It can lead to heart-related complications including blood clots, stroke, and heart failure. Left untreated, AF can double the risk of heart-related death and increase stroke risk by as much as five times in patients.
About Heart Rhythm Society
The Heart Rhythm Society’s 38th Annual Scientific Sessions convenes the finest clinicians, scientists, researchers and innovators in the field of cardiac pacing and electrophysiology. More than 800 of the worlds’ most noted experts in cardiac rhythm management serve as faculty for more than 250 educational sessions while more than 130 exhibitors showcase innovative products and services. Attendees can anticipate an enhanced experience with advanced learning formats and new opportunities for networking.
About MEDICALgorithmics S.A.
MEDICALgorithmics S.A. (WSE:MDG) is a leader in arrhythmia diagnostic solutions. Its PocketECG solution is used for remote monitoring of cardiac disorders, arrhythmia diagnosis, and heart-rate monitoring around the world. It is also used in clinical trials to evaluate the efficacy of new therapeutic methods.
In addition, MEDICALgorithmics S.A. provides services in the field of information technology, biotechnology and scientific research. The Company is also developing several other products, including a device for cardiac rehabilitation, software for optimizing repetitive tasks in hospitals, and algorithms for remote interpretation of multi-lead electrocardiography (ECG) signals. Based in Poland, it operates in the United States through MEDICALGORITHMICS US HOLDING CORPORATION and Medi-Lynx Cardiac Monitoring LLC, the US service provider and subsidiary to MEDICALgorithmics S.A.
For media inquiries:
SOURCE MEDICALgorithmics S.A.